MIRA PHARMACEUTICALS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 28, 2024, covering events occurring on June 24, 2024, and June 26, 2024. MIRA Pharmaceuticals, Inc. is an emerging growth company incorporated in Florida, with its principal executive offices in Miami. The company's common stock trades on The Nasdaq Capital Market under the symbol "MIRA."
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses on corporate governance and executive compensation adjustments.
Material Changes
- Executive Compensation Adjustment: On June 26, 2024, the Company entered into an Amended and Restated Employment Agreement with Michelle Yanez, Chief Financial Officer. Her annual base salary was reduced from $225,000 to $137,500.
- Work Arrangement: Ms. Yanez is required to work a minimum of 30 hours per week for MIRA Pharmaceuticals. The agreement acknowledges her ability to provide services to other companies owned or controlled by Bay Shore Trust and its affiliates, including Telomir Pharmaceuticals, Inc., where she was appointed CFO on June 18, 2024.
- Corporate Governance: The Company announced its first Annual Meeting of Shareholders is scheduled for September 12, 2024.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business performance. The primary risk disclosed relates to the allocation of the CFO's time between MIRA Pharmaceuticals and affiliated entities. The filing notes that shareholder proposals and director nominations for the upcoming Annual Meeting must be received by July 12, 2024, to be considered timely.
Key Facts for Investor Verification
- Verify the extent of Michelle Yanez's involvement with Telomir Pharmaceuticals, Inc. and other Bay Shore Trust affiliates to assess potential conflicts of interest or resource dilution.
- Confirm the date and agenda of the 2024 Annual Meeting of Shareholders scheduled for September 12, 2024.
- Review the full text of the Amended and Restated Employment Agreement (Exhibit 10.1) for details on severance, benefits, and termination provisions not summarized in this report.
- Monitor the upcoming proxy statement for details on director nominations and shareholder proposals.